Sabine Fuerst‐Recktenwald

Safety, efficacy and weight effect of two 11β‐ <scp>HSD1</scp> inhibitors in metformin‐treated patients with type 2 diabetes

Tim Heise, Linda Morrow, Marcus Hompesch et al. · Diabetes Obesity and Metabolism · 2014 · 43 citations

SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)

Eugenio Mercuri, Nina Barišić, Odile Boespflug‐Tanguy et al. · Neurology · 2020 · 30 citations

Lumbar Spine, Spinal Cord Injury, Sunfish Study +11

Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial

Francesco Muntoni, Enrico Bertini, Giacomo P. Comi et al. · Neuromuscular Disorders · 2020 · 27 citations · Full text

FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)

Laurent Servais, Giovanni Baranello, Riccardo Masson et al. · Neurology · 2020 · 25 citations

Type 1, Firefish Study, Firefish Part 2 +7

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

Dietmar Schwab, Carolina Sturm, Agnès Portron et al. · BMJ Open Ophthalmology · 2017 · 14 citations · Full text